News

News & publications

Company announcements and the peer-reviewed science behind Kinimmune’s approach.

Press Releases
March 3, 2023 | Business Wire
Kinimmune publishes results from a Phase I “Window of Opportunity” trial in patients with solid tumors
November 9, 2022 | Business Wire
Kinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors
Publications
2026 | International Journal of Pharmaceutics
Lyophilized Formulation Development and Characterization of Stable Glatiramer Acetate / Oligonucleotide Polyplexes at Clinically Therapeutic Strengths
2025 | Drug Delivery and Translational Research
Intralesional Injection of CpG ODNs Complexed with Glatiramer Acetate Mitigates Systemic Cytokine Toxicities and Synergistically Advances Checkpoint Blockade Efficacy
2025 | ChemRxiv
Lyophilized Formulation Development and Characterization of Stable Glatiramer Acetate / Oligonucleotide Polyplexes at Clinically Therapeutic Strengths
2024 | Cancer Research, AACR
Glatiramer Acetate Enhances Tumor Retention and Mitigates Systemic Toxicity of Toll-like Receptor 9 Agonists as Intratumoral Immunotherapy
2024 | Molecular Pharmaceutics
Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
2023 | Translational Medicine Communications
A Window of Opportunity Trial Evaluating Intratumoral Injection of Copaxone® in Patients with Percutaneously Accessible Tumors
2023 | Molecular Pharmaceutics
Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors
2022 | Molecular Pharmaceutics
Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1
2020 | Journal of Controlled Release
Human Intratumoral Therapy: Linking Drug Properties and Tumor Transport of Drugs in Clinical Trials
2020 | Journal of Pharmaceutical Sciences
Immunostimulant Complexed With Polylysine Limits Transport and Maintains Immune Cell Activation
2019 | Journal of Controlled Release
Formulation and Preclinical Evaluation of a Toll-like Receptor 7/8 Agonist as an Anti-tumoral Immunomodulator